Clinical Trial Update: Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the safety and efficacy of Balstilimab in combination with Botensilimab for non-small cell lung cancer (IMMONC0008) is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Balstilimab (balstilimab)
• Botensilimab (botensilimab)

Snippet

Sponsor: Immune Oncology Research Institute | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING